Midamor
(amiloride)ApprovedSmall molecule
Amiloride is a water pill used to treat high blood pressure and heart failure. Unlike other diuretics, it helps the body eliminate excess water and salt while preserving potassium, making it especially useful for patients who are at risk of having too-low potassium levels.[2] Midamor is currently approved and in use across 10 indications[4].[1]
Midamor is one of 286 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.
10
Indications
34
Total Trials
4
Active Trials
285
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Midamor
PPadagis LLC
Approved
Lexiscan
AstellasPreclinical
Voltaren
NovartisPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Duragesic-100
CCephalon
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hypertension9 trials
Show 6 more trials
Study of Amiloride on Vascular Phenotypes in Young Adults With Prehypertension
Unknown status·—·Phase 4·NCT01308983·32 enrolled
Comparison of Optimal Hypertension Regimens
Completed·—·Phase 4·NCT02847338·940 enrolled
Chronic Kidney Disease3 trials
Kidney Disease2 trials
Cardiovascular1 trial
Migraine1 trial
Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura
Recruiting·—·Phase 2·NCT04063540·40 enrolled
18 more indications
Multiple Sclerosis1 trial
Breast Cancer1 trial
Cystic Fibrosis1 trial
Treatment1 trial
Amiloride Hydrochloride as an Effective Treatment for ADHD
Terminated·SState University of New York - Upstate Medical University·Phase 1·NCT01733680·3 enrolled
Primary Hyperparathyroidism1 trial
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism
Completed·—·Phase 2/3·NCT02525796·69 enrolled
Type 2 Diabetes1 trial
Drug Repurposing1 trial
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
Completed·—··NCT05125237·155,963 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
MIDAMOR
NDA NDA018200
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Midamor drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for amiloride. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Amiloride-Sensitive Sodium Channel, Enac Blocker[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- PPadagis LLC